ELSIconversations - Pharmacogenomic Testing (PGx) in Psychiatric Care: Exploring Ethical and Regulatory Frontiers, Session 2

Session title: Exploring Ethical, Equity, and Regulatory Implications for Pharmacogenomics in Psychiatric Care Settings

Duke Margolis Institute for Health Policy and CERA Collaboration

There are many personal and health system level factors that affect the widespread adoption of pharmacogenomics informed treatments in psychiatric care settings. However, many ethical, legal, and social implication (ELSI) questions and challenges remain under-explored in both research and practice settings. For instance, who has access to pharmacogenomics research, testing and/or informed treatment in psychiatric care settings and why? What are ethics and equity implications to consider and address regarding pharmacogenomic testing in psychiatric care settings?

Moderator: Rachele Hendricks Sturrup, DHSc, MSc, MA

Speakers: Sandra E. Yankah, PhD, Deepak Voora, MD, Robert Schuck, PharmD, PhD, Gary Proctor, MD